| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,715 |
9,257 |
$629K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,597 |
1,975 |
$197K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,090 |
723 |
$155K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,038 |
6,665 |
$139K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,918 |
2,002 |
$119K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,842 |
2,813 |
$103K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
766 |
707 |
$63K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,320 |
1,681 |
$54K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
559 |
477 |
$43K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
947 |
782 |
$42K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
523 |
513 |
$40K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
478 |
279 |
$36K |
| 90651 |
|
287 |
262 |
$15K |
| 96160 |
|
925 |
847 |
$13K |
| 90686 |
|
1,170 |
945 |
$13K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
169 |
148 |
$12K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
170 |
132 |
$9K |
| 0071A |
|
208 |
193 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
332 |
262 |
$8K |
| 0072A |
|
173 |
172 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
579 |
483 |
$7K |
| 0001A |
|
104 |
104 |
$4K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
264 |
247 |
$4K |
| 0002A |
|
83 |
83 |
$3K |
| 99051 |
|
909 |
472 |
$3K |
| 83655 |
|
217 |
209 |
$3K |
| 90734 |
|
177 |
170 |
$2K |
| 0003A |
|
42 |
40 |
$2K |
| 90620 |
|
107 |
91 |
$1K |
| 90661 |
|
78 |
77 |
$1K |
| 36416 |
|
244 |
232 |
$967.60 |
| 90648 |
|
112 |
94 |
$821.44 |
| 0124A |
|
18 |
13 |
$752.40 |
| 90688 |
|
87 |
60 |
$663.84 |
| 85018 |
|
261 |
249 |
$605.52 |
| 94762 |
|
734 |
515 |
$569.40 |
| 90670 |
|
76 |
65 |
$480.00 |
| 90715 |
|
43 |
40 |
$419.54 |
| 90633 |
|
16 |
14 |
$263.21 |
| 90723 |
|
28 |
25 |
$179.20 |
| 86580 |
|
42 |
41 |
$168.00 |
| 90716 |
|
12 |
12 |
$76.80 |
| 90707 |
|
12 |
12 |
$76.80 |
| 91300 |
|
119 |
100 |
$0.35 |
| 3074F |
|
1,737 |
1,519 |
$0.00 |
| 1220F |
|
605 |
560 |
$0.00 |
| 1036F |
|
827 |
720 |
$0.00 |
| 91307 |
|
369 |
340 |
$0.00 |
| 4045F |
|
960 |
641 |
$0.00 |
| 96161 |
|
18 |
15 |
$0.00 |
| 1159F |
|
14,407 |
10,612 |
$0.00 |
| 90461 |
|
1,523 |
1,206 |
$0.00 |
| 1003F |
|
821 |
770 |
$0.00 |
| 3078F |
|
1,709 |
1,493 |
$0.00 |
| 4274F |
|
918 |
747 |
$0.00 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,516 |
2,930 |
$0.00 |
| 1160F |
|
14,404 |
10,608 |
$0.00 |
| 4120F |
|
425 |
412 |
$0.00 |
| 3210F |
|
947 |
635 |
$0.00 |
| 4124F |
|
29 |
28 |
$0.00 |
| 91312 |
|
18 |
13 |
$0.00 |